Login / Signup

SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination.

Andrea JarischEliza WiercinskaShabnam Daqiq-MirdadHelen HellsternSalem AjibAnjali CremerNgoc Thien Thu NguyenAlexandra DukatEvelyn UllrichSandra CiesekKai-Uwe ChowHubert ServeErhard SeifriedPeter BaderHalvard BonigGesine Bug
Published in: European journal of immunology (2022)
Little is known about the cellular immune response to SARS-CoV-2 vaccination in patients after HSCT and B-NHL with iatrogenic B-cell aplasia. In nonseroconverted HSCT patients, induction of specific T-cell responses was assessed. The majority of allogeneic HSCT patients not showing humoral responses to vaccination also fail to mount antigen-specific T-cell responses.
Keyphrases
  • sars cov
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • prognostic factors
  • stem cell transplantation
  • coronavirus disease
  • immune response